dihydroergotamine has been researched along with clozapine in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Batink, H; de Jonge, A; Thoolen, MJ; Timmermans, PB; van Zwieten, PA; Wilffert, B | 1 |
| Hamblin, MW; Monsma, FJ; Shen, Y; Sibley, DR; Ward, RP | 1 |
| Arrang, JM; Diaz, J; Leurs, R; Ruat, M; Schwartz, JC; Tardivel-Lacombe, J; Traiffort, E | 1 |
| Boess, FG; Monsma, FJ; Sleight, AJ | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Alelyunas, YW; Bui, K; Empfield, JR; McCarthy, D; Pelosi-Kilby, L; Shen, C; Spreen, RC | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
1 review(s) available for dihydroergotamine and clozapine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
7 other study(ies) available for dihydroergotamine and clozapine
| Article | Year |
|---|---|
Quantitative relationships between alpha-adrenergic activity and binding affinity of alpha-adrenoceptor agonists and antagonists.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Binding, Competitive; Blood Pressure; Brain; Cell Membrane; Clonidine; Kinetics; Prazosin; Quinazolines; Rats; Receptors, Adrenergic, alpha; Structure-Activity Relationship; Vasoconstriction | 1984 |
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
Topics: Amino Acid Sequence; Animals; Base Sequence; Binding, Competitive; Blotting, Northern; Brain Chemistry; Cell Line; Cloning, Molecular; DNA; GTP-Binding Proteins; Lysergic Acid Diethylamide; Molecular Sequence Data; Polymerase Chain Reaction; Psychotropic Drugs; Rats; Receptors, Serotonin; RNA; Serotonin; Serotonin Antagonists; Serotonin Receptor Agonists; Transfection | 1993 |
Molecular cloning, characterization, and localization of a high-affinity serotonin receptor (5-HT7) activating cAMP formation.
Topics: Amino Acid Sequence; Animals; Base Sequence; Blotting, Northern; Brain; CHO Cells; Cricetinae; Cyclic AMP; DNA; Genomic Library; Kinetics; Lysergic Acid Diethylamide; Mianserin; Molecular Sequence Data; Multigene Family; Oligodeoxyribonucleotides; Organ Specificity; Rats; Receptors, Serotonin; Restriction Mapping; Serotonin; Serotonin Receptor Agonists; Transfection | 1993 |
Identification of residues in transmembrane regions III and VI that contribute to the ligand binding site of the serotonin 5-HT6 receptor.
Topics: Adenylyl Cyclases; Amino Acid Substitution; Binding Sites; Binding, Competitive; Cell Line; Cyclic AMP; Humans; Ligands; Lysergic Acid Diethylamide; Mutagenesis, Site-Directed; Mutation; Receptors, Serotonin; Serotonin; Serotonin Receptor Agonists | 1998 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Experimental solubility profiling of marketed CNS drugs, exploring solubility limit of CNS discovery candidate.
Topics: Central Nervous System Agents; Drug Evaluation, Preclinical; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Solubility | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |